Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

Bolli, Niccolo, Avet-Loiseau, Hervé, Wedge, David C., Van Loo, Peter, Alexandrov, Ludmil B., Martincorena, Inigo, Dawson, Kevin J., Iorio, Francesco +27 more·2014·Nature Communications
DOI 10.1038/ncomms3997

Cited by (875)

Items 101–200 of 875

  1. Accurate quantification of copy-number aberrations and whole-genome duplications in multi-sample tumor sequencing data
    Simone Zaccaria, Benjamin J. Raphael · 2020 · Nature Communications
  2. Minimal residual disease in multiple myeloma: bringing the bench to the bedside
    Sham Mailankody, Neha Korde, Alexander M. Lesokhin, Nikoletta K. Lendvai, Hani Hassoun, Maryalice Stetler‐Stevenson, Ola Landgren · 2015 · Nature Reviews Clinical Oncology
  3. The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma
    Seweryn Mroczek, Justyna Chlebowska, Tomasz M. Kuliński, Olga Gewartowska, Jakub Gruchota, Dominik Cysewski, Vladyslava Liudkovska, Ewa Borsuk, Dominika Nowis, Andrzej Dziembowski · 2017 · Nature Communications
  4. Understanding mutagenesis through delineation of mutational signatures in human cancer
    Petljak, Mia, Alexandrov, Ludmil B. · 2016 · Carcinogenesis
  5. Mutational History of a Human Cell Lineage from Somatic to Induced Pluripotent Stem Cells
    Foad J. Rouhani, Serena Nik‐Zainal, Arthur Wüster, Yilong Li, Nathalie Conte, Hiroko Koike-Yusa, Natsuhiko Kumasaka, Ludovic Vallier, Kosuke Yusa, Allan Bradley · 2016 · PLoS Genetics
  6. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines
    Francesco Maura, Mia Petljak, Marta Lionetti, Ingrid Cifola, Winnie S. Liang, Eva Pinatel, Ludmil B. Alexandrov, Anthony Fullam, Sancha Martin, Kevin J. Dawson et al. · 2017 · Leukemia
  7. Genomics of Multiple Myeloma
    Sébastien Robiou-du-Pont, Alice Cleynen, Charlotte Fontan, Michel Attal, Nikhil C. Munshi, Jill Corre, Hervé Avet‐Loiseau · 2017 · Journal of Clinical Oncology
  8. Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
    Ignacio J. Cardona‐Benavides, Cristina De Ramón, Norma Carmen Gutierrez · 2021 · Cells
  9. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance
    Bruno Paiva, Luis Antonio Corchete, María‐Belén Vídriales, Noemí Puig, Patricia Maiso, Idoia Rodríguez, Diego Alignani, Leire Burgos, María-Luz Sánchez, Paloma Bárcena et al. · 2016 · Blood
  10. Inhibiting MEK in MAPK pathway-activated myeloma
    Christoph Johann Heuck, Yogesh S. Jethava, Rashid Z Khan, Frits van Rhee, Maurizio Zangari, Shweta S. Chavan, K Robbins, S E Miller, Aasiya Matin, Meera Mohan et al. · 2015 · Leukemia
  11. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma
    Gullà, A, Hideshima, T, Bianchi, G, Fulciniti, M, Kemal Samur, M, Qi, J, Tai, Y-T, Harada, T, Morelli, E, Amodio, N et al. · 2018 · Leukemia
  12. CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.
    Joseph D. Malaer, Porunelloor Abraham Mathew · 2017 · PubMed Central
  13. Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome
    Subramanian Venkatesan, Charles Swanton · 2016 · American Society of Clinical Oncology Educational Book
  14. Development of CAR-T cell therapies for multiple myeloma
    Nico Gagelmann, Kristoffer Riecken, Christine Wolschke, Carolina Berger, Francis Ayuketang Ayuk, Boris Fehse, Nicolaus Kröger · 2020 · Leukemia
  15. Molecular signatures of multiple myeloma progression through single cell RNA-Seq
    Jin Sung Jang, Ying Li, Amit Mitra, Lintao Bi, Alexej S. Abyzov, André J. van Wijnen, Linda Banovic Baughn, Brian Van Ness, S. Vincent Rajkumar, Shaji Kunnathu Kumar et al. · 2019 · Blood Cancer Journal
  16. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
    Skerget, Sheri, Penaherrera, Daniel, Chari, Ajai, Jagannath, Sundar, Siegel, David S., Vij, Ravi, Orloff, Gregory, Jakubowiak, Andrzej, Niesvizky, Ruben, Liles, Darla et al. · 2024 · Nature Genetics
  17. Epigenetics in multiple myeloma: From mechanisms to therapy
    Mohammad Alzrigat, Alba Atienza Párraga, Helena Jernberg‐Wiklund · 2017 · Seminars in Cancer Biology
  18. TPL2 kinase regulates the inflammatory milieu of the myeloma niche
    Chelsea L. Hope, Samuel J. Ollar, Erika Héninger, Ellen Hebron, Jeffrey Lee Jensen, Jaehyup Kim, Ioanna G Maroulakou, Shigeki Miyamoto, Catherine P. Leith, David T. Yang et al. · 2014 · Blood
  19. Genetic and Non-Genetic Mechanisms Underlying Cancer Evolution
    Yelyzaveta Shlyakhtina, Katherine L. Moran, Maximiliano M. Portal · 2021 · Cancers
  20. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
    Nizar Jacques Bahlis, Rachid Baz, Simon J. Harrison, Hang Quach, Shir-Jing Ho, Annette Juul Vangsted, Torben Plesner, Philippe Moreau, Simon DJ Gibbs, Sheryl Coppola et al. · 2021 · Journal of Clinical Oncology
  21. The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence In Situ Hybridization in Multiple Myeloma
    Gang An, Zengjun Li, Yu‐Tzu Tai, Chirag Acharya, Qian Li, Xiaoqi Qin, Shuhua Yi, Yan Xu, Xiaoyan Feng, Chengwen Li et al. · 2015 · Clinical Cancer Research
  22. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma
    Liang Lin, Shih‐Feng Cho, Lijie Xing, Kenneth Wen, Yuyin Li, Tengteng Yu, Phillip A. Hsieh, Hailin Chen, Metin Kurtoğlu, Yi Zhang et al. · 2020 · Leukemia
  23. Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
    Xu, J, Pfarr, N, Endris, V, Mai, E K, Md Hanafiah, N H, Lehners, N, Penzel, R, Weichert, W, Ho, A D, Schirmacher, P et al. · 2017 · Oncogenesis
  24. KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival
    Hiroto Ohguchi, Takeshi Harada, M Sagawa, Shohei Kikuchi, Y-T Tai, Paul Gerard Guy Richardson, Teru Hideshima, Kenneth Carl Anderson · 2017 · Leukemia
  25. Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms
    Phuc H. Hoang, Sara E. Dobbins, Alex J. Cornish, Daniel Chubb, Philip Law, Martin Kaiser, Richard S. Houlston · 2018 · Leukemia
  26. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Luciano J. Costa, Faith E. Davies, Gregory P. Monohan, Tibor J. Kovacsovics, Nicholas R. Burwick, Andrzej J. Jakubowiak, Jonathan L. Kaufman, Wan‐Jen Hong, Monique Dail, Ahmed Hamed Salem et al. · 2021 · Blood Advances
  27. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
    Margaux Lejeune, Murat Cem Köse, Elodie Duray, Hermann Einsele, Yves P. Beguin, Jo Caers · 2020 · Frontiers in Immunology
  28. Promising therapies in multiple myeloma
    Giada Bianchi, Paul Gerard Guy Richardson, Kenneth Carl Anderson · 2015 · Blood
  29. New paradigms in clonal evolution: punctuated equilibrium in cancer
    William C. H. Cross, Trevor A. Graham, Nicholas A Wright · 2016 · The Journal of Pathology
  30. The NF-κB Activating Pathways in Multiple Myeloma
    Payel Roy, Uday Aditya Sarkar, Soumen Basak · 2018 · Biomedicines
  31. A community effort to create standards for evaluating tumor subclonal reconstruction
    DREAM SMC-Het Participants, Adriana Salcedo, Maxime Tarabichi, Shadrielle M. G. Espiritu, Amit G. Deshwar, Matei David, Nathan M. Wilson, Stefan C. Dentro, Jeff A. Wintersinger, Lydia Liu et al. · 2020 · Nature Biotechnology
  32. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition
    Rizq, Ola, Mimura, Naoya, Oshima, Motohiko, Saraya, Atsunori, Koide, Shuhei, Kato, Yuko, Aoyama, Kazumasa, Nakajima-Takagi, Yaeko, Wang, Changshan, Chiba, Tetsuhiro et al. · 2017 · Clinical Cancer Research
  33. Multiple Myeloma Therapy: Emerging Trends and Challenges
    Danai Dima, Dongxu Jiang, Divya Jyoti Singh, Metis Hasipek, Haikoo Shah, Fauzia Ullah, Jack Khouri, Jaroslaw Pawel Maciejewski, Babal Kant Jha · 2022 · Cancers
  34. Timing somatic events in the evolution of cancer
    Clemency Jolly, Peter Van Loo · 2018 · Genome biology
  35. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients
    John R Jones, Niels Weinhold, Cody Ashby, Brian A. Walker, Christopher P. Wardell, Charlotte Pawlyn, Leo Rasche, Lorenzo Melchor, David Allan Cairns, Walter Martin Gregory et al. · 2019 · Haematologica
  36. The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma
    Leo Rasche, Klaus Martin Kortüm, Marc Steffen Raab, Niels Weinhold · 2019 · International Journal of Molecular Sciences
  37. The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
    Leo Rasche, Carolina Schinke, Francesco Maura, Michael Bauer, Cody Ashby, Shayu Deshpande, Alexandra Maria Poos, Maurizio Zangari, Sharmilan Thanendrarajan, Faith E. Davies et al. · 2022 · Nature Communications
  38. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma
    Niccolò Bolli, Y Li, Vijitha Sathiaseelan, Keiran M. Raine, David Jones, Peter S. Ganly, Federica Cocito, Graham R. Bignell, M A Chapman, Adam Samuel Sperling et al. · 2016 · Blood Cancer Journal
  39. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)
    Matthew Ho, Ashish S Patel, Chia Yin Goh, Maria Moscvin, Li Zhang, Giada Bianchi · 2020 · Leukemia
  40. Germline risk of clonal haematopoiesis
    Alexander J. Silver, Alexander G. Bick, Michael Robert Savona · 2021 · Nature Reviews Genetics
  41. The emerging roles of NGS in clinical oncology and personalized medicine
    Bashdar Mahmud Hussen, Sara Tharwat Abdullah, Abbas Burhan Salihi, Dana Khdr Sabir, Karzan R. Sidiq, Mohammed Fatih Rasul, Hazha Jamal Hidayat, Soudeh Ghafouri‐Fard, Mohammad Naser Taheri, Elena Jamali · 2022 · Pathology - Research and Practice
  42. The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma
    Salomon Manier, John T. Powers, Antonio Sacco, Siobhan V. Glavey, Daisy Huynh, Michaela Ruth Reagan, Karma Ziad Salem, Michele Moschetta, Jiantao Shi, Yuji Mishima et al. · 2016 · Leukemia
  43. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
    Teresa Paíno, Bruno Paiva, José María Sayagués, Inês Andrade Mota, Tiago Carvalheiro, Luis Antonio Corchete, Irene Aires‐Mejía, José Juan Pérez, María Luz Sánchez, Paloma Bárcena et al. · 2014 · Leukemia
  44. Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome
    Annamaria Brioli, Hannah Victoria Giles, Charlotte Pawlyn, John P. Campbell, Martin Kaiser, Lorenzo Melchor, Graham Hunter Jackson, Walter Martin Gregory, Roger G. Owen, J. Anthony Child et al. · 2014 · Blood
  45. Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92
    Eugenio Morelli, Lavinia Biamonte, Cinzia Federico, Nicola Amodio, Maria Teresa Di Martino, Maria Eugenia Gallo Cantafio, Martina Manzoni, Francesca Scionti, Mehmet Samur, Annamaria Gullà et al. · 2018 · Blood
  46. Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma
    Ayesha Noorani, Xiaodun Li, Martin J Goddard, Jason Crawte, Ludmil B. Alexandrov, Maria Secrier, Matthew Eldridge, Lawrence Bower, Jamie M. J. Weaver, Pierre Lao-Sirieix et al. · 2020 · Nature Genetics
  47. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation
    Marta Lionetti, Marzia Barbieri, Katia Todoerti, Luca Agnelli, Simona Marzorati, Sonia Fabris, Gabriella Ciceri, Serena Galletti, Giulia Milesi, Martina Manzoni et al. · 2015 · Oncotarget
  48. Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance
    Veronika Vikova, Michel Jourdan, Nicolas Robert, Guilhem Requirand, Stéphanie Boireau, Angélique Bruyer, Laure Vincent, Guillaume Cartron, Bernard Klein, Olivier Elemento et al. · 2019 · Theranostics
  49. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations
    Charlotte Pawlyn, Lorenzo Melchor, Alex Murison, Christopher P. Wardell, Annamaria Brioli, Eileen Mary Boyle, Martin Kaiser, Brian A. Walker, Dil B Begum, Nasrin B. Dahir et al. · 2014 · Blood
  50. PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation
    Zhihong Ren, Jeong Hyun Ahn, Hequn Liu, Yi‐Hsuan Tsai, Natarajan V. Bhanu, Brian S. Koss, David F. Allison, Anqi Ma, Aaron J. Storey, Ping Wang et al. · 2019 · Blood
  51. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma
    Bachisio Ziccheddu, Giulia Biancon, Filippo Bagnoli, Chiara De Philippis, Francesco Maura, Even Holth Rustad, Matteo Dugo, Andrea Devecchi, Loris De Cecco, Marialuisa Sensi et al. · 2020 · Blood Advances
  52. Activating KRAS , NRAS , and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma
    Fazal Shirazi, Richard Julian Jones, Ram K. Singh, Jianxuan Zou, Isere Kuiatse, Zuzana Berkova, Hua Wang, Hans Chulhee Lee, Samuel Hong, Lawrence R. Dick et al. · 2020 · Proceedings of the National Academy of Sciences
  53. Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
    Sherry Bhalla, David T. Melnekoff, Adolfo Aleman, Violetta V. Leshchenko, Paula Restrepo, Jonathan J. Keats, Kenan Onel, Jeffrey R. Sawyer, Deepu Madduri, Joshua Ryan Richter et al. · 2021 · Science Advances
  54. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
    Chenggong Li, Jia Li Xu, Wenjing Luo, Danying Liao, Wei Xie, Qiuzhe Wei, Yinqiang Zhang, Xindi Wang, Zhuolin Wu, Yun Jin Kang et al. · 2023 · Leukemia
  55. Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy
    Kinan Alhallak, Jennifer Sun, Katherine Wasden, Nicole Guenthner, Julie O’Neal, Barbara Muz, Justin A. King, Daniel R. Kohnen, Ravi Vij, Samuel Achilefu et al. · 2021 · Leukemia
  56. The Tao of myeloma
    Lawrence Boise, Jonathan L. Kaufman, Nizar Jacques Bahlis, Sagar Lonial, Kelvin P. Lee · 2014 · Blood
  57. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target
    Prasoon Agarwal, Mohammad Alzrigat, Alba Atienza Párraga, Stefan Enroth, Umashankar Singh, Johanna S. Ungerstedt, Anders Österborg, Peter J. Brown, Anqi Ma, Jian Jun Jin et al. · 2016 · Oncotarget
  58. Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors
    Amit Mitra, Ujjal Kumar Mukherjee, Taylor Harding, Jin Sung Jang, Holly A.F. Stessman, Yafei Li, Alexej S. Abyzov, Jin Jen, Shaji Kunnathu Kumar, S. Vincent Rajkumar et al. · 2015 · Leukemia
  59. Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy
    Dan J. Woodcock, Е. В. Рябченко, Sinja Taavitsainen, Matti Kankainen, Gunes Gundem, Daniel S. Brewer, Pekka Ellonen, Maija Lepistö, Y. A. Golubeva, Andrew Warner et al. · 2020 · Nature Communications
  60. The spectrum of APOBEC3 activity: From anti-viral agents to anti-cancer opportunities
    Abby M. Green, Matthew D. Weitzman · 2019 · DNA repair
  61. Genome-wide somatic alterations in multiple myeloma reveal a superior outcome group
    Samur, Mehmet Kemal, Aktas Samur, Anil, Fulciniti, Mariateresa, Szalat, Raphael, Han, Tessa, Shammas, Masood, Richardson, Paul, Magrangeas, Florence, Minvielle, Stephane, Corre, Jill et al. · 2020 · Journal of Clinical Oncology
  62. Extramedullary Waldenström macroglobulinemia
    Ranjit Banwait, Yosra M. Aljawai, Joseph M. Cappuccio, Serena McDiarmid, Elizabeth A. Morgan, Houry Leblebjian, Aldo Maria Roccaro, Jacob P. Laubach, Jorge Julio Castillo, Claudia E. Paba‐Prada et al. · 2014 · American Journal of Hematology
  63. Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response
    Arash Latifoltojar, Margaret Anne Hall-Craggs, Neil K. Rabin, Rakesh Popat, Alan P Bainbridge, Νικόλαος Δικαίος, Magdalena Sokolska, Ali Rismani, Shirley D’Sa, Shonit Punwani et al. · 2016 · British Journal of Haematology
  64. Accelerated single cell seeding in relapsed multiple myeloma
    Heather Jolie Landau, Venkata D. Yellapantula, Benjamin T. Diamond, Even Holth Rustad, Kylee H. Maclachlan, Gunes Gundem, Juan Santiago Medina-Martinez, Juan Arango Ossa, Max Fine Levine, Yangyu Zhou et al. · 2020 · Nature Communications
  65. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma
    Alessandro Laganà, Deepak Perumal, David T. Melnekoff, Ben Readhead, Brian A. Kidd, Violetta V. Leshchenko, P-Y Kuo, Jonathan J. Keats, Mary DeRome, Jennifer Yesil et al. · 2017 · Leukemia
  66. IKZF1/3 and CRL4<sup>CRBN</sup> E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma
    Barrio, Santiago, Munawar, Umair, Zhu, Yuan Xiao, Giesen, Nicola, Shi, Chang-Xin, Viá, Matteo Da, Sanchez, Ricardo, Bruins, Laura, Demler, Theresa, Müller, Nicole et al. · 2020 · Haematologica
  67. Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
    Klaus Podar, Xavier P Leleu · 2021 · Cancers
  68. Molecular pathogenesis of multiple myeloma
    Yusuke Furukawa, Jiro Kikuchi · 2015 · International Journal of Clinical Oncology
  69. The molecular spectrum and clinical impact of DIS 3 mutations in multiple myeloma
    Susann Weißbach, Christian Langer, Bernhard Puppe, Theodora Nedeva, Elisa Bach, Miriam Kull, Ralf Christian Bargou, Hermann Einsele, Andreas Rosenwald, Stefan Tobias Knop et al. · 2014 · British Journal of Haematology
  70. Loss of FAM46C Promotes Cell Survival in Myeloma
    Yuan Xiao Zhu, Chang-Xin Shi, Laura Ann Bruins, Patrick Michael Jedlowski, Xuewei Wang, Klaus Martin Kortüm, Moulun Luo, Jonathan M. Ahmann, Esteban Braggio, A. Keith Stewart · 2017 · Cancer Research
  71. Comprehensive characterisation of intronic mis-splicing mutations in human cancers
    Hyunchul Jung, Kang Seon Lee, Jung Kyoon Choi · 2021 · Oncogene
  72. Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes
    Naser Ansari‐Pour, Yonglan Zheng, Toshio F. Yoshimatsu, Ayodele Sanni, Mustapha Ajani, Jean-Baptiste Reynier, Avraam Tapinos, Jason J. Pitt, Stefan C. Dentro, Anna Woodard et al. · 2021 · Nature Communications
  73. Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns
    Ingrid Cifola, Marta Lionetti, Eva Pinatel, Katia Todoerti, Eleonora Mangano, Alessandro Pietrelli, Sonia Fabris, Laura Mosca, Vittorio Simeon, Maria Teresa Petrucci et al. · 2015 · Oncotarget
  74. Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
    Solimando, Antonio Giovanni, Malerba, Eleonora, Leone, Patrizia, Prete, Marcella, Terragna, Carolina, Cavo, Michele, Racanelli, Vito · 2022 · Frontiers in Oncology
  75. Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing
    Mattia D’Agostino, Gian Maria Zaccaria, Bachisio Ziccheddu, Even Holth Rustad, Elisa Genuardi, Andréa Capra, Stefania Oliva, Daniel Auclair, Jennifer Yesil, Paola Colucci et al. · 2020 · Clinical Cancer Research
  76. MRD in multiple myeloma: does CR really matter?
    Bruno Paiva, Jesús F. San Miguel, Hervé Avet‐Loiseau · 2022 · Blood
  77. Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis
    Alexandra Maria Poos, Nina Prokoph, Moritz Jakob Przybilla, Jan‐Philipp Mallm, Simon Steiger, Isabelle Seufert, Lukas John, Stephan M. Tirier, Katharina Bauer, Anja Baumann et al. · 2023 · Blood
  78. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma
    Yusuke Furukawa, Jiro Kikuchi · 2016 · International Journal of Hematology
  79. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment
    Daniela Belloni, Silvia Heltai, Maurilio Ponzoni, Antonello Villa, Barbara Vergani, Lorenza Pecciarini, Magda Marcatti, Stefania Girlanda, Giovanni Tonon, Fabio Ciceri et al. · 2018 · Haematologica
  80. Gene Expression Profiles in Myeloma: Ready for the Real World?
    Raphael Elie Szalat, Hervé Avet‐Loiseau, Nikhil C. Munshi · 2016 · Clinical Cancer Research
  81. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
    Shweta S. Chavan, Jie He, Ruslana G. Tytarenko, S Deshpande, Pragi Patel, M Bailey, Joshua Epstein, Owen Stephens, Niels Weinhold, Nathan M. Petty et al. · 2017 · Blood Cancer Journal
  82. Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
    Jinhuan Xu, Qiuxiang Wang, Hao Xu, Chaojiang Gu, Lijun Jiang, Jue Wang, Di Wang, Bin Xu, Xia Mao, Jin Wang et al. · 2018 · Journal of Hematology & Oncology
  83. High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
    Antonio Giovanni Solimando, Matteo Da Vià, Sebastiano Cicco, Patrizia Leone, Giuseppe Di Lernia, Donato Giannico, Vanessa Desantis, Maria Antonia Frassanito, Arcangelo Morizio, Julia Delgado Tascon et al. · 2019 · Journal of Clinical Medicine
  84. Gene expression profile alone is inadequate in predicting complete response in multiple myeloma
    Samirkumar B. Amin, W-K Yip, Stéphane Minvielle, Annemiek Broyl, Y Li, Bret M. Hanlon, David Michael Swanson, Parantu K. Shah, Philippe Moreau, Bronno van der Holt et al. · 2014 · Leukemia
  85. SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization
    Yi Qiao, Aaron R. Quinlan, Amir Anthony Jazaeri, Roel G.W. Verhaak, David A. Wheeler, Gábor Marth · 2014 · Genome biology
  86. The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential
    Bieghs, Liesbeth, Johnsen, Hans E., Maes, Ken, Menu, Eline, Van Valckenborgh, Els, Overgaard, Michael T., Nyegaard, Mette, Conover, Cheryl A., Vanderkerken, Karin, De Bruyne, Elke · 2016 · Oncotarget
  87. Panobinostat for the Management of Multiple Myeloma
    Dharshan Sivaraj, Michael M Green, Cristina Gasparetto · 2016 · Future Oncology
  88. RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response
    Isabel Juliana Hofman, Mark van Duin, E De Bruyne, Laura Fancello, George Mulligan, E Geerdens, Emanuela Garelli, Cecilia Mancini, H Lemmens, M Delforge et al. · 2016 · Leukemia
  89. Phosphonate and Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthases: A Structure-Guided Perspective
    Jae-Ok Park, Vishal Pandya, Sean J. Ezekiel, Albert Marinus Berghuis · 2021 · Frontiers in Chemistry
  90. Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
    Lorraine N. Davis, Daniel W. Sherbenou · 2021 · Cancers
  91. Implications of Heterogeneity in Multiple Myeloma
    Sanjay De Mel, Su Hong Lim, Moon Ley Tung, Wee Joo Chng · 2014 · BioMed Research International
  92. Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing
    Guangwu Guo, Noopur S Raje, Charles Seifer, Jake A. Kloeber, Randi Isenhart, Gavin Ha, Andrew Jenho Yee, Elizabeth O’Donnell, Yu‐Tzu Tai, Paul Gerard Guy Richardson et al. · 2018 · Leukemia
  93. The Making of a PreCancer Atlas: Promises, Challenges, and Opportunities
    Sudhir Srivastava, Sharmistha Ghosh, Jacob Kagan, Richard V. Mazurchuk, Emily S. Boja, Rodrigo F. Chuaqui, Eric Chavarria-Johnson, Tanja M. Davidsen, Janet F. Eary, Todd Haim et al. · 2018 · Trends in cancer
  94. A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma
    Lijie Xing, Liang Lin, Tengteng Yu, Yuyin Li, Shih‐Feng Cho, Jiye Liu, Kenneth Wen, Phillip A. Hsieh, Krista Kinneer, Nikhil C. Munshi et al. · 2020 · Leukemia
  95. Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance
    Mehmet Baysal, Ufuk Demirci, Elif Gülsüm Ümıt, Hakkı Onur Kırkızlar, Emine İkbal Atlı, Hakan Gürkan, Sedanur Karaman Gülsaran, Volkan Baş, Cisem Mail, Ahmet Muzaffer Demir · 2020 · Scientific Reports
  96. CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement
    Matteo Da Vià, Antonio Giovanni Solimando, Andoni Garitano-Trojaola, Santiago Barrio, Umair Munawar, Susanne Strifler, Larissa Haertle, Nadine Rhodes, Eva Teufel, Cornelia Vogt et al. · 2019 · The Oncologist
  97. In utero origin of myelofibrosis presenting in adult monozygotic twins
    Nikolaos Sousos, Máire Ní Leathlobhair, Christina Simoglou Karali, Eleni Louka, Nicola Bienz, Daniel J. Royston, Sally‐Ann Clark, Angela D. Hamblin, Kieran Howard, Vikram Mathews et al. · 2022 · Nature Medicine
  98. Nucleotide excision repair is a potential therapeutic target in multiple myeloma
    Raphael Elie Szalat, Mehmet Samur, Mariateresa Fulciniti, Michael A. Lopez, Puru Nanjappa, Alice Cleynen, Kenneth Wen, Sushil Kumar, Tommaso Perini, Anne S. Calkins et al. · 2017 · Leukemia
  99. A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5
    Brian S. White, Irena Lanc, Julie O’Neal, Harshath Gupta, Robert S. Fulton, Heather K. Schmidt, Catrina C. Fronick, Edward A. Belter, Mark Aaron Fiala, Justin A. King et al. · 2018 · Blood Cancer Journal
  100. The RNA Exosome and Human Disease
    Milo B. Fasken, Derrick Jerone Morton, Emily G. Kuiper, Stephanie K. Jones, Sara W. Leung, Anita H. Corbett · 2019 · Methods in molecular biology